AR077931A2 - Anticuerpos contra la interleuquina-13 humana y usos de los mismos - Google Patents
Anticuerpos contra la interleuquina-13 humana y usos de los mismosInfo
- Publication number
- AR077931A2 AR077931A2 ARP100103010A ARP100103010A AR077931A2 AR 077931 A2 AR077931 A2 AR 077931A2 AR P100103010 A ARP100103010 A AR P100103010A AR P100103010 A ARP100103010 A AR P100103010A AR 077931 A2 AR077931 A2 AR 077931A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- light chain
- cdr3
- domain
- sequence
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 7
- 102000018358 immunoglobulin Human genes 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 102000003816 Interleukin-13 Human genes 0.000 abstract 5
- 108090000176 Interleukin-13 Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000244186 Ascaris Species 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000019207 human interleukin-13 Human genes 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000003843 mucus production Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se posee además una composicion farmacéutica que comprende el anticuerpo divulgado; una célula huésped; un método para proporcionar un anticuerpo recombinante; un método para tratar un trastorno asociado con la IL-13. Reivindicacion 1: Un anticuerpo o un fragmento del mismo de union al antígeno, que se une a la IL-13 con un KD de menos de 5 x 10-7 M y que tiene una o más de las propiedades siguientes: (a) la secuencia variable del dominio de inmunoglobulina de cadena pesada comprende una CDR3 pesada de mAb13.2 (SEQ ID Ns 24), o una CDR3 que difiere por menos de 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; (b) la secuencia variable de dominio de inmunoglobulina de cadena liviana comprende una CDR3 de cadena liviana de mAb13.2 (SEO ID Ns 21), o una CDR3 que difiere por menos de 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; (c) la secuencia variable de dominio de inmunoglobulina de cadena pesada comprende una secuencia codificada por un ácido nucleico que hibridiza bajo condiciones muy rigurosas hasta el complemento de un ácido nucleico que codifica un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 11, 12 o 35); (d) la secuencia variable de dominio de inmunoglobulina de cadena liviana comprende una secuencia codificada por un ácido nucleico que hibridiza bajo condiciones muy rigurosas hasta el complemento de un ácido nucleico que codifica un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); (e) la secuencia variable de dominio de inmunoglobulina de cadena pesada es por lo menos 90% idéntica a un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 11, 12 o 35); (f) la secuencia variable de dominio de inmunoglobulina de cadena liviana es por lo menos 90% idéntica a un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); (g) la proteína compite con mAb13.2 para unirse a la IL-13 humana; (h) la proteína entra en contacto con uno o más aminoácidos de IL-13 seleccionados a partir del grupo que consiste en 68, 72, 88, 91, 92, 93, y 105 de la SEQ ID Ns 31; (i) la secuencia de dominio variable de cadena pesada tiene la misma estructura canonica que mAb13.2; (j) la secuencia variable de dominio de cadena liviana tiene la misma estructura canonica que mAb13.2; y (k) confiere un efecto protector posterior a la inyeccion contra la exposicion al antígeno de Ascaris en un modelo de oveja por lo menos 6 semanas después de la inyeccion. Reivindicacion 18: Un ácido nucleico que comprende una secuencia que (i) codifica un polipéptido que comprende una secuencia variable de dominio de inmunoglobulina de cadena liviana que: (a) comprende a una CDR3 de cadena liviana de mAb13.2 (SEQ ID Ns 21), o una CDR3 que difiere por menos en 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; o (b) es por lo menos 90% idéntica a un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); o (ii) hibridiza bajo condiciones muy rigurosas al complemento de un ácido nucleico que codifica un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 15, 16 o 36). Reivindicacion 45: Un método para tratar a un paciente que presenta un síntoma de asma seleccionado a partir del grupo que consiste en respiracion dificultosa, falta de aliento, broncoconstriccion, hipersensibilidad de las vías aéreas, disminucion de la capacidad pulmonar, fibrosis, inflamacion de las vías aéreas, y produccion de moco, dicho método comprende el paso de administrar al paciente un anticuerpo que se une a la IL-13 e interfiere con la formacion de un complejo funcional de senalizacion de la IL-13.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57873604P | 2004-06-09 | 2004-06-09 | |
US57847304P | 2004-06-09 | 2004-06-09 | |
US58137504P | 2004-06-22 | 2004-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077931A2 true AR077931A2 (es) | 2011-10-05 |
Family
ID=35503715
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102343A AR049390A1 (es) | 2004-06-09 | 2005-06-08 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
ARP100103010A AR077931A2 (es) | 2004-06-09 | 2010-08-17 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102343A AR049390A1 (es) | 2004-06-09 | 2005-06-08 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
Country Status (19)
Country | Link |
---|---|
US (2) | US7615213B2 (es) |
EP (3) | EP1756161A2 (es) |
JP (4) | JP2008515776A (es) |
KR (3) | KR101462878B1 (es) |
CN (2) | CN101141980B (es) |
AR (2) | AR049390A1 (es) |
AU (2) | AU2005253981B2 (es) |
BR (2) | BRPI0510881A (es) |
CA (2) | CA2567129A1 (es) |
CR (2) | CR8784A (es) |
EC (2) | ECSP067072A (es) |
IL (2) | IL179093A0 (es) |
MX (2) | MXPA06014298A (es) |
NO (2) | NO20070087L (es) |
NZ (1) | NZ582046A (es) |
RU (2) | RU2427589C2 (es) |
SG (2) | SG135207A1 (es) |
TW (1) | TWI391133B (es) |
WO (2) | WO2005123126A2 (es) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
PT1703893E (pt) | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP2008520684A (ja) * | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Il−13に対する完全ヒトモノクローナル抗体 |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
EP1877074B1 (en) | 2005-04-15 | 2013-03-27 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells |
AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
US20070237763A1 (en) * | 2005-10-06 | 2007-10-11 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
KR20080049113A (ko) * | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
AU2006330858A1 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
TW200804593A (en) * | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
AU2007227292B2 (en) * | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
EP2006381B1 (en) * | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
JP2010514409A (ja) * | 2006-06-21 | 2010-05-06 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトの癌における鑑別式サイトカイン発現 |
WO2008003514A2 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
AU2007292253A1 (en) * | 2006-09-08 | 2008-03-13 | Wyeth | Arginine wash in protein purification using affinity chromatography |
AU2007351514B2 (en) | 2006-09-08 | 2013-02-21 | Abbvie Inc. | Interleukin -13 binding proteins |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
BRPI0719250A2 (pt) * | 2006-10-12 | 2015-06-16 | Wyeth Corp | Métodos e composições com opalescência reduzida. |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008057240A2 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
MX2009005725A (es) * | 2006-12-11 | 2009-08-24 | Wyeth Corp | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. |
CA2674608A1 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
CA2675233A1 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
MX2009009080A (es) * | 2007-02-23 | 2009-11-02 | Schering Corp | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. |
DK2426144T3 (en) | 2007-02-23 | 2019-01-07 | Merck Sharp & Dohme | Manipulated Anti-IL-23P19 Antibodies |
EP2527364A1 (en) * | 2007-03-29 | 2012-11-28 | Abbott Laboratories | Crystalline anti-human IL-12 antibodies |
RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
US7890055B1 (en) * | 2007-07-09 | 2011-02-15 | Everlokt Corporation | Touch field compound field detector personal ID |
RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2009106163A (ja) * | 2007-10-26 | 2009-05-21 | Kyushu Univ | 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー |
US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
ES2834741T3 (es) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-NR10 y uso del mismo |
CN102037011A (zh) | 2008-03-18 | 2011-04-27 | 雅培制药有限公司 | 用于治疗银屑病的方法 |
CA2728909A1 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
US8399630B2 (en) | 2008-08-20 | 2013-03-19 | Centocor Ortho Biotech Inc. | Engineered anti-IL-13 antibodies, compositions, methods and uses |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010054212A1 (en) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
US20120177668A1 (en) * | 2009-07-06 | 2012-07-12 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
MX2012004711A (es) * | 2009-10-20 | 2012-05-23 | Abbott Lab | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a. |
WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
MY166429A (en) | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重v區類抗體蛋白質之用途 |
KR20140061403A (ko) | 2011-07-13 | 2014-05-21 | 애브비 인코포레이티드 | 항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물 |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
DK2948134T3 (da) | 2013-01-24 | 2020-06-02 | Palvella Therapeutics Inc | Sammensætninger til transdermal indgivelse af mtor-inhibitorer |
AR095774A1 (es) * | 2013-04-05 | 2015-11-11 | Genentech Inc | Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos |
NZ718144A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
KR20160068802A (ko) | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | 호산구성 장애를 진단 및 치료하는 방법 |
CR20160379A (es) | 2014-02-21 | 2016-10-07 | Genentech Inc | Anticuerpos biespecificos anti-il 13/il-17 y sus usos |
CA2943707A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20230044338A (ko) | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
KR102557643B1 (ko) | 2016-09-23 | 2023-07-20 | 제넨테크, 인크. | 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도 |
WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
KR20230142806A (ko) | 2018-02-09 | 2023-10-11 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
MA52011A (fr) | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
EP3941589A1 (en) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CN113677708A (zh) * | 2019-03-26 | 2021-11-19 | 亚狮康私人有限公司 | 采用抗il13r抗体或其结合片段的治疗 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN114605535A (zh) * | 2020-12-08 | 2022-06-10 | 深圳福沃药业有限公司 | 抗il-13抗体及其用途 |
BR112023017490A2 (pt) | 2021-03-17 | 2023-11-07 | Receptos Llc | Métodos de tratamento de dermatite atópica com anticorpos anti il-13 |
CN118076636A (zh) | 2021-09-15 | 2024-05-24 | 德米拉公司 | Il-13抑制剂用于治疗结节性痒疹 |
CA3235096A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
ZA9010190B (en) | 1989-12-20 | 1991-08-28 | Schering Corp | Antibody antagonists of human interleukin-4 |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5246701A (en) | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
MD1652G2 (ro) | 1991-03-29 | 2001-12-31 | Sanofi-Synthelabo | Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
EP0721469B1 (en) | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antibodies and uses therefor |
US5928904A (en) | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US20010053371A1 (en) | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
CA2238080C (en) | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
WO1997033913A1 (en) | 1996-03-13 | 1997-09-18 | Zymogenetics, Inc. | Cytokine-receptor expressed in testis cells |
EP0812913A3 (en) | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
AU6175696A (en) | 1996-06-12 | 1998-01-07 | Human Genome Sciences, Inc. | Hr-1 receptor |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
BR9714523A (pt) | 1997-01-10 | 2000-05-02 | Biogen Inc | Tratamento de nefrite de lúpus com compostos anti-cd40l |
US6387615B2 (en) | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9723553D0 (en) | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
PT1141286E (pt) | 1998-12-14 | 2007-01-31 | Genetics Inst Llc | Cadeia de receptores de citocina |
US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01008142A (es) | 1999-02-10 | 2003-07-21 | Welfide Corp | Compuestos de amida, y uso medicinal de los mismos. |
AU5756100A (en) | 1999-06-21 | 2001-01-09 | Genetics Institute Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
AU2000278349A1 (en) | 1999-09-28 | 2001-04-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
EP1222212A4 (en) | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
WO2001077332A2 (en) | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
WO2002055100A2 (en) | 2000-10-20 | 2002-07-18 | Genetics Institute, Llc | Method and composition for inhibition of tumor growth and enhancing an immune response |
IL156618A0 (en) * | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
US6649935B2 (en) | 2001-02-28 | 2003-11-18 | International Business Machines Corporation | Self-aligned, planarized thin-film transistors, devices employing the same |
GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
US7216242B2 (en) * | 2001-03-16 | 2007-05-08 | Dualcor Technologies, Inc. | Personal electronics device with appliance drive features |
AUPR544401A0 (en) * | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
EP1402451A4 (en) | 2001-06-07 | 2005-01-05 | Wyeth Corp | SOLUTION STRUCTURE OF IL-13 AND USE THEREOF |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20030023555A1 (en) | 2001-07-26 | 2003-01-30 | Cashworks, Inc. | Method and system for providing financial services |
CA2842429A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
US20040234499A1 (en) | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
WO2003035847A2 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
US20040248260A1 (en) | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
US20050154192A1 (en) | 2001-11-27 | 2005-07-14 | Kamon Shirakawa | Anti-il13 receptor alpha1 neutralizing antibody |
EP1455833A1 (en) | 2001-12-04 | 2004-09-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
EP1325868A1 (en) | 2002-01-08 | 2003-07-09 | Tetra Laval Holdings & Finance SA | Packaging unit for continuously producing sealed packages, containing pourable food products, from a tube of packaging material |
JP4432031B2 (ja) | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ.エルティーディー. | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
WO2003092610A2 (en) | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
EP1552462B1 (en) | 2002-06-14 | 2011-03-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods of treating and preventing colitis involving il-13 and nk-t cells |
JP2004121218A (ja) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
US20060104943A1 (en) * | 2002-08-30 | 2006-05-18 | Claire Ashman | Vaccine comprising il-13 and an adjuvant |
EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
EP1651266B1 (en) | 2003-07-25 | 2010-03-03 | Laboratorios Silanes, S.A. de C.V. | Administration of anti-tnf-alpha f(ab')2 antibody fragments |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
PT1703893E (pt) | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
JP2007525210A (ja) * | 2003-12-24 | 2007-09-06 | ワイス | 喘息の処置方法 |
EP1713441A2 (en) | 2004-02-12 | 2006-10-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
CA2557724A1 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
MX2009005725A (es) | 2006-12-11 | 2009-08-24 | Wyeth Corp | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. |
RU2009140134A (ru) | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
-
2005
- 2005-06-08 AR ARP050102343A patent/AR049390A1/es active IP Right Grant
- 2005-06-09 JP JP2007527730A patent/JP2008515776A/ja not_active Withdrawn
- 2005-06-09 EP EP05786816A patent/EP1756161A2/en not_active Withdrawn
- 2005-06-09 KR KR1020137008282A patent/KR101462878B1/ko not_active IP Right Cessation
- 2005-06-09 US US11/149,309 patent/US7615213B2/en not_active Expired - Fee Related
- 2005-06-09 BR BRPI0510881-0A patent/BRPI0510881A/pt not_active IP Right Cessation
- 2005-06-09 SG SG200706331-6A patent/SG135207A1/en unknown
- 2005-06-09 EP EP05786668A patent/EP1765401A4/en not_active Withdrawn
- 2005-06-09 MX MXPA06014298A patent/MXPA06014298A/es unknown
- 2005-06-09 JP JP2007527694A patent/JP4970258B2/ja not_active Expired - Fee Related
- 2005-06-09 NZ NZ582046A patent/NZ582046A/en not_active IP Right Cessation
- 2005-06-09 RU RU2006140793/10A patent/RU2427589C2/ru not_active IP Right Cessation
- 2005-06-09 AU AU2005253981A patent/AU2005253981B2/en not_active Ceased
- 2005-06-09 WO PCT/US2005/020160 patent/WO2005123126A2/en active Application Filing
- 2005-06-09 RU RU2006140096/13A patent/RU2006140096A/ru not_active Application Discontinuation
- 2005-06-09 SG SG200905834-8A patent/SG155260A1/en unknown
- 2005-06-09 KR KR1020067025945A patent/KR20070034487A/ko not_active Application Discontinuation
- 2005-06-09 CA CA002567129A patent/CA2567129A1/en not_active Abandoned
- 2005-06-09 MX MXPA06014299A patent/MXPA06014299A/es active IP Right Grant
- 2005-06-09 WO PCT/US2005/020334 patent/WO2005121177A2/en active Application Filing
- 2005-06-09 KR KR1020067025990A patent/KR101299073B1/ko not_active IP Right Cessation
- 2005-06-09 CN CN2005800191385A patent/CN101141980B/zh not_active Expired - Fee Related
- 2005-06-09 BR BRPI0511910-3A patent/BRPI0511910A/pt not_active IP Right Cessation
- 2005-06-09 TW TW094119110A patent/TWI391133B/zh active
- 2005-06-09 CA CA002567081A patent/CA2567081A1/en not_active Abandoned
- 2005-06-09 EP EP12169663A patent/EP2548889A1/en not_active Withdrawn
- 2005-06-09 AU AU2005252700A patent/AU2005252700A1/en not_active Withdrawn
- 2005-06-09 CN CN2012102800731A patent/CN102827280A/zh active Pending
-
2006
- 2006-11-07 IL IL179093A patent/IL179093A0/en unknown
- 2006-11-22 IL IL179476A patent/IL179476A/en not_active IP Right Cessation
- 2006-12-05 CR CR8784A patent/CR8784A/es not_active Application Discontinuation
- 2006-12-05 CR CR8783A patent/CR8783A/es not_active Application Discontinuation
- 2006-12-11 EC EC2006007072A patent/ECSP067072A/es unknown
- 2006-12-11 EC EC2006007073A patent/ECSP067073A/es unknown
-
2007
- 2007-01-05 NO NO20070087A patent/NO20070087L/no not_active Application Discontinuation
- 2007-01-08 NO NO20070133A patent/NO20070133L/no unknown
-
2009
- 2009-10-08 US US12/575,896 patent/US8221752B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 AR ARP100103010A patent/AR077931A2/es unknown
-
2011
- 2011-03-09 JP JP2011051866A patent/JP2011155980A/ja active Pending
-
2014
- 2014-08-20 JP JP2014167064A patent/JP2015037401A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077931A2 (es) | Anticuerpos contra la interleuquina-13 humana y usos de los mismos | |
Tan et al. | Venom-gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah) | |
BRPI0606368A2 (pt) | anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de hibridoma | |
JP2019038834A (ja) | 分泌様免疫グロブリンを含む組成物 | |
JP2008515446A5 (es) | ||
CN102471765A (zh) | 显示出缩短的生物学活性的神经毒素 | |
SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
CA2969635C (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
CA2704119C (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibodies | |
US20120329994A1 (en) | Production of a Monoclonal Antibody Therapeutic Against West Nile Virus in Plants | |
EP3805255A1 (en) | Acinetobacter baumannii immunogenic protein and composition and application thereof | |
TW201522379A (zh) | Chrdl-1抗原結合蛋白及治療方法 | |
Liu et al. | Purification and characterization of parvalbumins from silver carp (Hypophthalmichthy molitrix) | |
RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
DE69840105D1 (de) | Plättchen-spezifische antigene und deren pharmazeutische verwendung | |
US11505619B2 (en) | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease | |
JP2019503341A (ja) | 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達 | |
CN107531798A (zh) | Pcsk9的抑制剂用于脂蛋白代谢病症的治疗 | |
CN109071614B (zh) | 肺炎球菌溶血素ply截短胜肽及其用途 | |
Abe et al. | The presence of the 50-kDa subunit of dynactin complex in the nerve growth cone | |
TW201725213A (zh) | 一種利用雙硫鍵重組技術製造抗蛇毒血清之方法及其產物 | |
Wang et al. | Identification of Linear IgE Epitopes for a Major Allergen-Type I Collagen in Fish (Rainbow Trout). | |
AR125224A1 (es) | Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos | |
AR041606A1 (es) | Anticuerpos contra el receptor de eritropoyetina | |
Nuzzo et al. | Amino acid substitution in Par j 2 recombinant allergen and its effect on IgE binding capacity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |